Cadrenal Therapeutics Phase 2 HIT trial: primary endpoint missed, thrombotic events reduced >25%

Cadrenal Therapeutics, Inc.

Platelet count recovery (primary endpoint) did not differ between CAD-1005 and placebo arms.
Thrombotic events: >75% in placebo vs 50% in CAD-1005 group (>25% absolute reduction).
End-of-Phase 2 meeting with FDA scheduled for March 2026 to discuss Phase 3 path.
CAD-1005 is the only 12-LOX inhibitor in clinical development worldwide.
Trial concluded December 2025 after program transfer from Veralox Therapeutics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.